Verification of the Combimatrix influenza detection assay for the detection of influenza A subtype during the 2007–2008 influenza season in Toronto, Canada

被引：0

作者：

Shelly Bolotin

Ernesto Lombos

Rani Yeung

AliReza Eshaghi

Joanne Blair

Steven J Drews

机构：

[1] Ontario Agency for Health Protection and Promotion,Department of Microbiology

[2] Mount Sinai Hospital,Department of Laboratory Medicine and Pathobiology

[3] University of Toronto,undefined

来源：

Virology Journal | / 6卷

关键词：

Influenza; Respiratory Syncytial Virus; H1N1 Virus; Oseltamivir; Influenza Season;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

The increase in adamantine resistance in influenza A (H3N2) and the emergence of oseltamivir resistance in influenza A (H1N1) has necessitated the use of rapid methodologies to detect influenza subtype. The purpose of this study was to evaluate the CombiMatrix influenza detection system compared to the FDA approved Luminex Respiratory virus panel (RVP) assay for influenza A subtyping. Verification of the CombiMatrix influenza detection system was carried out using the Luminex RVP assay as a reference method. A limit of detection (LOD) series was performed using the Luminex and CombiMatrix systems with both influenza A H3N2 and H1N1 viruses. Seventy-five clinical specimens were used in the study. Of these, 16 were influenza A (H3N2) positive and five were influenza A (H1N1) positive. Fifty-four specimens were influenza A negative or "no call" (inconclusive) or could not be subtyped. The LOD of the Luminex RVP assay was found to be 0.3 TCID50s/mL for influenza A (H3N2) and 16 TCID50s/mL for influenza A (H1N1). The LOD of the CombiMatrix influenza detection system was 200 TCID50s/mL for influenza A (H3N2) and 16 000 TCID50s/mL for influenza A (H1N1). The sensitivity of the CombiMatrix influenza detection system was 95.2% and the specificity was 100%. The CombiMatrix influenza detection system is an effective methodology for influenza A subtype analysis, specifically in laboratories with a constrained budget or limited molecular capabilities.

引用

共 54 条

[1]

Bright RA(2006)Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States JAMA 295 891-894

[2]

Shay DK(2008)Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004–2008 Antimicrob Agents Chemother 52 3284-3292

[3]

Shu B(2000)Application of a fluorogenic PCR assay for typing and subtyping of influenza viruses in respiratory samples J Clin Microbiol 38 1552-1558

[4]

Cox NJ(2002)Influenza virus types and subtypes detection by single step single tube multiplex reverse transcription-polymerase chain reaction (RT-PCR) and agarose gel electrophoresis J Virol Methods 99 63-70

[5]

Klimov AI(2008)For the proposition: for the diagnosis of viral infections, commercial assays provide more reliable results than do in-house assays Rev Med Virol 18 73-76

[6]

Sheu TG(2008)Against the proposition: for the diagnosis of viral infections, commercial assays provide more reliable results than do in-house assays Rev Med Virol 18 77-80

[7]

Deyde VM(2008)Comparison of the Luminex xTAG respiratory viral panel with in-house nucleic acid amplification tests for diagnosis of respiratory virus infections J Clin Microbiol 46 3056-3062

[8]

Okomo-Adhiambo M(2007)Development of a respiratory virus panel test for detection of twenty human respiratory viruses by use of multiplex PCR and a fluid microbead-based assay J Clin Microbiol 45 2965-2970

[9]

Garten R(2006)Use of semiconductor-based oligonucleotide microarrays for influenza a virus subtype identification and sequencing J Clin Microbiol 44 1209-1218

[10]

Xu X(2007)CombiMatrix oligonucleotide arrays: genotyping and gene expression assays employing electrochemical detection Biosens Bioelectron 22 1853-1860

← 1 2 3 4 5 6 →